
BioLight Israeli Life Sciences Investments Ltd
Focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions,.
BioLight | Investments Ltd. English עברית Skip to content Home Strategy Management Our Pipeline XLVision Micromedic Investor Relations Contact BioLight Innovation in Ophthalmology We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome, or DES, and age-related macular degeneration, or AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications. Our goal is to be a leading global ophthalmic company by building a diverse and balanced portfolio of innovative products and product candidates, establishing a sales force to maximize the commercial potential of our products, maintaining a global, diverse network of ophthalmic specialists and accelerating knowledge synergies and innovation. We plan to add products and product candidates to our pipeline by expanding our current platform technologies to additional indications and through in-licensing and investing in new platform technologies, technologies, products and product candidates. Leading key investors, holding about 55% of BioLights issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, Indias largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel and Rock One A Hong Kong investment based company. BioLight is a public traded company on the Tel-Aviv Stock Exchange (BOLT). News Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test 26 July 2016 BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome 19 May 2016 BioLight Reports 2015 Financial Results 5 April 2016 BioLight Files Registration Statement for Proposed Initial Public Offering in the United States 10 February 2016 Positive Second Clinical Study Results for its TeaRx 7 January 2016 BioLight Announces Closing of Joint Investment in IOPtima Subsidiary 30 December 2015 IOPtiMate System Receives Regulatory Approval in Canada 21 December 2015 First IOPtiMate System Sale in Portugal 8 December 2015 Third Quarter 2015 Financial Results 1 December 2015 Partnership with Axella Research for CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer 30 November 2015 Corporate Presentation © BioLight Life Sciences Ltd. Home Terms of Use Contact us Site Development Site2goal | Design Telescope